Risk-Benefit Ratio of Sodium Fluoride Treatment in Primary Vertebral Osteoporosis

Mamelle, N.; Dusan, R.; Martin, Jean‐Louis; Prost, A.; Meunier, Pierre J.; Guillaume, Maéva; Gaucher, Alison; Zeigler, G.; Netter, Patrick

doi:10.1016/s0140-6736(88)92834-6

Cited by 218 publications

(57 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In several of the studies reviewed here, fluoride treatment was associated with a significantly increased incidence of lower extremity pain. 169,[172][173][174]176 In one trial, this was associated with significantly increased incidences of osteomalacia and microfractures of the lower extremities 168 and, in another, with a statistically significant increase in incomplete fissure fractures compared with placebo (RR = 13.00; 95% CI, 3.17 to 53.33). 172 In two trials, 75,115 patients in the fluoride group withdrew from the study because of stress fractures and, in one of these, some patients also withdrew from the fluoride group because of gastrointestinal symptoms.…”

Section: Side-effectsmentioning

confidence: 99%

“…75 Fluoride has also been associated with an increase in gastrointestinal complaints and several studies reported such complaints (pain, bloating, nausea or a change in bowel habit). 168,172,176 The incidence of such complaints decreased when enteric-coated tablets or capsules were used. 168 In one study, 72 a significant reduction in back pain was found in women treated with fluoride with or without alfacalcidol but not in those treated with alfacalcidol alone.…”

Section: Side-effectsmentioning

confidence: 99%

“…58,64,70,72,74-76,79,93,104.109,110,115,124,139,163,164,166,176, 190-195 The trials varied in their duration, the populations studied and the regimens used (see appendix 5). Of these trials, 18 were either stated to be open-label or there was no implication that they were blinded, for instance, by reference to the use of placebos, 64,72,[74][75][76]79,93,104,109,110,115,124,139,164,176,190,191,193,194 although in six of them the outcome assessors had been blinded to treatment status. 64,124,164,190,191,193 For further details of their methodological quality, see appendix 5.…”

Section: Comparisons With Active Treatmentsmentioning

confidence: 99%

“…Vertebral fracture was a primary outcome measure in seven studies 70,75,109,124,139,166,176 and a secondary outcome measure in a further ten. 58,72,104,110,115,190,[192][193][194][195] In six studies which included vertebral fracture as an outcome measure, there was no apparent differentiation between primary and secondary outcome measures.…”

Section: Comparisons With Active Treatmentsmentioning

confidence: 99%

“…74,76,79,163,164,191 Non-vertebral fracture was a primary outcome measure in one study 193 and a secondary outcome measure in a further eight. 70,75,109,110,115,124,176,192 It was mentioned in two further studies that did not appear to differentiate between primary and secondary outcome measures. 74,191 In one study, data were collected on symptomatic fractures only as part of adverse event reporting; vertebral and non-vertebral fractures were not reported separately.…”

Section: Comparisons With Active Treatmentsmentioning

confidence: 99%

See 4 more Smart Citations

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Kanis

Brazier

Stevenson

et al. 2002

Health Technol Assess

207

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.Paying by official purchase order You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.This has meant that the HTA panels can now focus more explicitly on health technologies ('health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care) rather than settings of care. Therefore the panel structure has been redefined and replaced by three new panels: Pharmaceuticals; Therapeutic Procedures (including devices and operations); and Diagnostic Technologies and Screening.The HTA Programme continues to commission both primary and secondary research. The HTA Commissioning Board, supported by the National Coordinating Centre for Health Technology Assessment (NCCHTA), will consider...

show abstract

Section: Side-effectsmentioning

confidence: 99%

Section: Side-effectsmentioning

confidence: 99%

Section: Comparisons With Active Treatmentsmentioning

confidence: 99%

Section: Comparisons With Active Treatmentsmentioning

confidence: 99%

Section: Comparisons With Active Treatmentsmentioning

confidence: 99%

See 3 more Smart Citations

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Kanis

Brazier

Stevenson

et al. 2002

Health Technol Assess

207

View full text Add to dashboard Cite

show abstract

Induction of stress response and differential expression of 70 kDa stress proteins by sodium fluoride in hela and rat brain tumor 9l cells

Cheng

Chen

et al. 1998

J. Cell. Biochem.

View full text Add to dashboard Cite

We herein demonstrate that sodium fluoride (NaF) acts as a stress response inducer on HeLa and 9L rat brain tumor cells. NaF is only slightly cytotoxic, and inhibitory to Ser/Thr-phosphatases but not to Tyr-phosphatases in both cell lines. After treatment with 5 mM NaF for 2 h, the phosphorylation levels of vimentin and an alkali-resistant 65-kDa phosphoprotein were enhanced, a common phenomenon detected in cells under a variety of stress conditions. Under an identical treatment protocol, in which the cells were treated with 5 mM NaF for 2 h and then allowed to recover under normal growing conditions for up to 12 h, NaF differentially induced the cytoplasmic/nuclear heat-shock protein70s (including both the inducible and the constitutively expressed members of this protein family) in HeLa cells and the endoplasmic reticulum residing heat-shock protein70 (the glucose-regulated protein with an apparent molecular weight of 78 kDa) in 9L cells. Electrophoretic mobility shift assays (EMSA) using probes containing well-characterized regulatory elements revealed the activation of the heat-shock factor in HeLa but not in 9L cells; this is in good agreement with the stress protein induction pattern. Additional differential induction of binding activities toward EMSA probes individually containing NF-KB, AP-2, and CRE-like elements were detected in NaF-treated cells. The possible involvement of these binding sites as well as the corresponding factors in the stress response are discussed.

show abstract

Measurement of total and diffusible serum fluoride

Rigalli¹,

Alloatti²,

Puche³

1999

J. Clin. Lab. Anal.

View full text Add to dashboard Cite

This article describes a technique for the measurement of total and diffusible F content of serum, at clinical significant concentrations of F (1–10 μM). The proposed procedure avoids the interference of unknown serum components with the ion‐specific electrode. Sample F is concentrated fivefold through distillation of hydrofluoric acid (Taves' method). Ionic fluoride is presented to the electrode in a simple solution at concentrations within the linear response of the electrode. Average recoveries of F from serum or its ultrafiltrate were 96 ± 7% (21%) and 97 ± 12% (53%) (mean ± SEM [CV]), respectively. With four replicates of each sample, the technique produce within‐run standard deviations of 0.6 μM and 2.2 μM at 1 and 10 μM F, respectively. Total precision assessment gave standard deviations of 0.6 μM and 2.6 μM at 1 and 10 μM F, respectively. The fasting serum F levels of normal climacteric women, 45 to 65 years, showed an asymmetric distribution. The data obtained started at the detection limit of the technique (0.1 mM). The 75 percentile was 1.85 μM for total and 0.5 μM for diffusible F. In patients (n = 25) treated with NaF (30 mg F/day) the fasting levels of total serum F (4.5 ± 1.7 μM) did not differ from those of diffusible F (4.2 ± 1.5 μM). In patients (n = 50) treated with sodium monofluorophosphate (15 mg F/day) the fasting levels of total and diffusible serum F were 6.5 ± 1.7 μM and 0.5 ± 0.03 μM, respectively.In conclusion, this paper establishes the presence of two fractions of serum fluorine: diffusible and nondiffusible (or protein bound) and describes a technique for their clinical estimation. In untreated subjects and in patients receiving NaF, the former fraction contains ionic fluoride. In patients treated with MFP, diffusible serum fluorine is composed by ionic fluoride and low molecular weight, peptide‐bound, acid‐labile fluorine. J. Clin. Lab. Anal. 13:151–157, 1999. © 1999 Wiley‐Liss, Inc.

show abstract

Risk-Benefit Ratio of Sodium Fluoride Treatment in Primary Vertebral Osteoporosis

Cited by 218 publications

References 9 publications

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Induction of stress response and differential expression of 70 kDa stress proteins by sodium fluoride in hela and rat brain tumor 9l cells

Measurement of total and diffusible serum fluoride

Contact Info

Product

Resources

About